Accessible version Definium Therapeutics MDD drug launch could be a life-saving trip; Initiate at Buy Initiating Coverage: BUY | PO: 75.00 USD | Price: 45.26 USD BIC data support big upside in large MDD/GAD markets We initiate DFTX at Buy with a $75 PO. DFTX is a late-stage clinical biopharmaceutical company developing proprietary forms of psychedelic and empathogenic drugs for brain health disorders. Their lead asset, DT120 (LSD), is in pivotal studies for major depressive disorder (MDD) and generalized an ...